These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 24387108)

  • 41. Relationships between signaling pathway usage and sensitivity to a pathway inhibitor: examination of trametinib responses in cultured breast cancer lines.
    Leung EY; Kim JE; Askarian-Amiri M; Rewcastle GW; Finlay GJ; Baguley BC
    PLoS One; 2014; 9(8):e105792. PubMed ID: 25170609
    [TBL] [Abstract][Full Text] [Related]  

  • 42. SB365 inhibits angiogenesis and induces apoptosis of hepatocellular carcinoma through modulation of PI3K/Akt/mTOR signaling pathway.
    Hong SW; Jung KH; Lee HS; Choi MJ; Son MK; Zheng HM; Hong SS
    Cancer Sci; 2012 Nov; 103(11):1929-37. PubMed ID: 22909393
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer.
    Awasthi N; Yen PL; Schwarz MA; Schwarz RE
    J Cell Biochem; 2012 Mar; 113(3):784-91. PubMed ID: 22020918
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma.
    Kanteti R; Dhanasingh I; Kawada I; Lennon FE; Arif Q; Bueno R; Hasina R; Husain AN; Vigneswaran W; Seiwert T; Kindler HL; Salgia R
    PLoS One; 2014; 9(9):e105919. PubMed ID: 25221930
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma.
    Rosich L; Montraveta A; Xargay-Torrent S; López-Guerra M; Roldán J; Aymerich M; Salaverria I; Beà S; Campo E; Pérez-Galán P; Roué G; Colomer D
    Oncotarget; 2014 Aug; 5(16):6788-800. PubMed ID: 25216518
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Multipoint targeting of the PI3K/mTOR pathway in mesothelioma.
    Zhou S; Liu L; Li H; Eilers G; Kuang Y; Shi S; Yan Z; Li X; Corson JM; Meng F; Zhou H; Sheng Q; Fletcher JA; Ou WB
    Br J Cancer; 2014 May; 110(10):2479-88. PubMed ID: 24762959
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia.
    Kampa-Schittenhelm KM; Heinrich MC; Akmut F; Rasp KH; Illing B; Döhner H; Döhner K; Schittenhelm MM
    Mol Cancer; 2013 May; 12():46. PubMed ID: 23705826
    [TBL] [Abstract][Full Text] [Related]  

  • 48. mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids.
    Gagliano T; Bellio M; Gentilin E; Molè D; Tagliati F; Schiavon M; Cavallesco NG; Andriolo LG; Ambrosio MR; Rea F; Degli Uberti E; Zatelli MC
    Endocr Relat Cancer; 2013 Aug; 20(4):463-75. PubMed ID: 23653462
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization.
    Kuger S; Flentje M; Djuzenova CS
    Radiat Oncol; 2015 Oct; 10():214. PubMed ID: 26498922
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells.
    Park HS; Hong SK; Oh MM; Yoon CY; Jeong SJ; Byun SS; Cheon J; Lee SE; Moon du G
    Anticancer Res; 2014 Jul; 34(7):3457-68. PubMed ID: 24982354
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combined targeting of mTOR and c-MET signaling pathways for effective management of epithelioid sarcoma.
    Imura Y; Yasui H; Outani H; Wakamatsu T; Hamada K; Nakai T; Yamada S; Myoui A; Araki N; Ueda T; Itoh K; Yoshikawa H; Naka N
    Mol Cancer; 2014 Aug; 13():185. PubMed ID: 25098767
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma.
    May CD; Landers SM; Bolshakov S; Ma X; Ingram DR; Kivlin CM; Watson KL; Sannaa GAA; Bhalla AD; Wang WL; Lazar AJ; Torres KE
    Cancer Biol Ther; 2017 Oct; 18(10):816-826. PubMed ID: 29099264
    [TBL] [Abstract][Full Text] [Related]  

  • 53. LY‑294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF‑1α pathway.
    Xu R; Zhang Y; Li A; Ma Y; Cai W; Song L; Xie Y; Zhou S; Cao W; Tang X
    Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 33982772
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
    Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
    Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma.
    Kim MN; Lee SM; Kim JS; Hwang SG
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):809-817. PubMed ID: 31385002
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Synergistic Anti-Cancer Effects of NVP-BEZ235 and Regorafenib in Hepatocellular Carcinoma.
    Yu CC; Huang SY; Chang SF; Liao KF; Chiu SC
    Molecules; 2020 May; 25(10):. PubMed ID: 32466169
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
    Li H; Jin X; Zhang Z; Xing Y; Kong X
    Cell Biochem Funct; 2013 Jul; 31(5):427-33. PubMed ID: 23086777
    [TBL] [Abstract][Full Text] [Related]  

  • 58. PI3K/mTOR dual-inhibition with VS-5584 enhances anti-leukemic efficacy of ponatinib in blasts and Ph-negative LSCs of chronic myeloid leukemia.
    Kayabasi C; Yelken BO; Asik A; Okcanoglu TB; Sogutlu F; Gasimli R; Susluer SY; Saydam G; Avci CB; Gunduz C
    Eur J Pharmacol; 2021 Nov; 910():174446. PubMed ID: 34461124
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
    Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
    Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
    Serova M; de Gramont A; Tijeras-Raballand A; Dos Santos C; Riveiro ME; Slimane K; Faivre S; Raymond E
    Cancer Chemother Pharmacol; 2013 May; 71(5):1297-307. PubMed ID: 23479136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.